Literature DB >> 1312038

Cycloheximide inhibits cellular, but not SV40, DNA replication.

D Schulte1, R Knippers, T Dreier, G Probst, H Probst.   

Abstract

We have prepared extracts from cycloheximide-treated cells for the study of simian-virus-40 (SV40)-DNA replication in vitro. When supplemented with the viral initiator protein (large T antigen), these extracts fully supported SV40-DNA replication. We also determined that SV40-DNA replication in vivo is much more resistant to cycloheximide than cellular DNA replication. SV40 encodes its own initiator protein, T antigen, which also functions as a DNA helicase, but depends on cellular functions for all additional replication reactions. Therefore, it appears to be quite likely that cycloheximide affects cellular DNA replication by blocking the synthesis of (a) cellular function(s) that is(are) performed by T antigen in SV40-DNA replication. Indeed, DNA fiber autoradiography and alkaline sucrose gradient centrifugation of pulse-labeled cellular DNA showed that cycloheximide treatment almost completely suppressed replicon initiation and reduced the rate of replication fork movement to about one third of the control.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312038     DOI: 10.1016/0014-5793(92)80235-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Selective and synchronous activation of early-S-phase replicons of Ehrlich ascites cells.

Authors:  V Gekeler; J Epple; G Kleymann; H Probst
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

2.  S-phase-dependent action of cycloheximide in relieving chromatin-mediated general transcriptional repression.

Authors:  M Cesari; L Héliot; C Meplan; M Pabion; S Khochbin
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

3.  Distinct mechanistic responses to replication fork stalling induced by either nucleotide or protein deprivation.

Authors:  Sofia Henriksson; Petra Groth; Nina Gustafsson; Thomas Helleday
Journal:  Cell Cycle       Date:  2018-04-02       Impact factor: 4.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.